Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Publication year range
1.
Actas urol. esp ; 47(4): 221-228, mayo 2023. tab, graf
Article in Spanish | IBECS | ID: ibc-219977

ABSTRACT

Introducción La nefroureterectomía radical (NFU) es el tratamiento estándar del carcinoma de tramo urinario superior (TUS). No obstante, desde 1985 se ha introducido el tratamiento conservador en el manejo del carcinoma in situ en TUS (cis-TUS). El objetivo de este estudio fue comparar la evolución oncológica de los pacientes con cis-TUS tratados en nuestro centro con NFU vs. instilaciones de bacilo de Calmette-Guérin (BCG). Métodos Se trata de un estudio retrospectivo de pacientes con diagnóstico de cis-TUS primario entre 1990-2018. Todos los pacientes presentaban diagnóstico histológico de cis-TUS con ausencia de otro carcinoma de TUS concomitante. La confirmación histológica se obtuvo mediante ureteroscopia con múltiples biopsias. Los pacientes fueron tratados mediante NFU, ureterectomía distal o instilaciones de BCG. Los datos clinicopatológicos y la evolución oncológica fue comparada entre los grupos NFU y BCG. Resultados Se incluyeron un total de 28 pacientes, 29 unidades renales (UR). Dieciséis (57,1%) pacientes (17 UR) recibieron BCG. Las instilaciones fueron administradas por nefrostomía en 4 pacientes, catéter en J simple en 5 y doble J en 7. La respuesta completa y la persistencia o recurrencia fueron detectadas en 10 (58,8%) y 7 (41,2) UR tratadas con BCG. Ocho UR (27,6%) fueron tratadas con NFU, con una recurrencia contralateral detectada en 4 casos (50%). Finalmente, 4 UR con cis-TUS (13,8%) fueron tratadas con ureterectomía distal. No se detectaron diferencias en la supervivencia libre de recurrencia (p=0,841) ni en la supervivencia cáncer específica (p=0,77) entre los grupos de NFU y BCG. Conclusiones Aunque la nefroureterectomía radical representa el tratamiento estándar para el CIS de tramo urinario superior, nuestros resultados confirman que las instilaciones con BCG también son efectivas. La confirmación histológica de cis-TUS debería realizarse previamente a la decisión terapéutica (AU)


Introduction Radical nephroureterectomy (RNU) still represents the gold standard treatment for upper tract urothelial carcinoma (UTUC); however, since the 1980s attempts have been made to treat upper urinary tract CIS (UT-CIS) conservatively. The aim of this study was to compare the outcome of patients with primary UT-CIS treated in our center by means of RNU vs. bacillus Calmette-Guérin (BCG) instillations. Methods This retrospective study included patients with diagnosis of primary UT-CIS between 1990 and 2018. All patients had histological confirmation of UT-CIS in the absence of other concomitant UTUC. Histological confirmation was obtained by ureteroscopy with multiple biopsies. Patients were treated with RNU, distal ureterectomy, or BCG instillations. Clinicopathological features and outcomes were compared between the RNU and BCG groups. Results A total of 28 patients and 29 renal units (RUs) were included. Sixteen (57.1%) patients (17 RUs) received BCG. BCG was administered via a nephrostomy tube in 4 patients, a single-J ureteral stent in 5, and a Double-J stent in 7. Complete response and persistence or recurrence were detected in ten (58.8%) and seven (41.2%) RUs treated with BCG, respectively. Eight (27.6%) RUs underwent RNU, with contralateral recurrence detected in four (50%), and 4 (13.8%) RUs underwent distal ureterectomy. No differences were found in recurrence-free survival (p=0.841) and cancer-specific survival (p=0.77) between the RNU and BCG groups. Conclusions Although RNU remains the gold standard treatment for UT-CIS, our results confirm that BCG instillations are also effective. Histological confirmation of UT-CIS is mandatory before any treatment (AU)


Subject(s)
Humans , Male , Female , Middle Aged , Aged , BCG Vaccine/therapeutic use , Carcinoma in Situ/surgery , Nephroureterectomy/methods , Urinary Bladder Neoplasms/pathology , Urinary Bladder Neoplasms/surgery , Biopsy , Retrospective Studies , Ureteroscopy/methods
2.
Actas Urol Esp (Engl Ed) ; 47(3): 159-164, 2023 04.
Article in English, Spanish | MEDLINE | ID: mdl-37013354

ABSTRACT

AIM: To measure the temperature dynamics at the renal surface and within the urinary tract when using Ho:YAG and Tm:YAG lasers for tissue ablation. MATERIALS AND METHODS: Porcine kidneys were used. Both types of lasers with different configurations and fiber sizes were used through a flexible ureteroscope. The temperature at the renal surface was recorded using a thermal camera while the intrarenal temperature was measured using two thermal probes, the first one at the ureteropelvic junction and the second one at the calyx used for lasering. Temperature was determined at 0.5-1-3-5 and 10 min. RESULTS: Recordings at the ureteropelvic junction and calyx revealed significant increases when using Tm:YAG with the 273 µm (10 W to 50 W) (p ≤ 0.02) and 550 µm (10 W) fiber (p = 0.04). With Ho:YAG there was a significant increase when using 273 µm (at 10 W and 20 W) (p ≤ 0.03) and 365 µm (10 W) fibers (p = 0.04). Regarding fiber size there was a significant difference when using Tm:YAG (at 20 W and 40 W) (p < 0.05). The thermal camera recorded a mean increase of 8 °C in the UPJ while the remaining areas of the kidney did not undergo significant changes. CONCLUSIONS: Temperature changes were greater when using the Ho:YAG laser with respect to Tm:YAG at similar power settings for tissue ablation. The greatest temperature increase was recorded at the UPJ from where the heat dissipated throughout the kidney.


Subject(s)
Lasers, Solid-State , Swine , Animals , Lasers, Solid-State/therapeutic use , Temperature , Thulium , Holmium , Kidney/surgery
3.
Actas urol. esp ; 47(3): 159-164, abr. 2023. ilus, graf
Article in Spanish | IBECS | ID: ibc-218405

ABSTRACT

Objetivo Medir la dinámica de la temperatura en la superficie renal y dentro de la vía urinaria al usar los láseres Ho:YAG y Tm:YAG para la ablación tisular. Materiales y métodos Se utilizaron riñones porcinos. Ambos tipos de láseres con diferentes configuraciones y tamaños de fibras se usaron a través de un ureteroscopio flexible. La temperatura en la superficie renal fue registrada mediante una cámara termográfica mientras que la intrarrenal fue medida a través de dos termómetros, el primero en la unión pieloureteral y el segundo en el cáliz elegido para el uso del láser. La temperatura fue determinada a los 0,5-1-3-5 y 10 minutos. Resultado Los registros en la unión pieloureteral y en el cáliz revelaron incrementos significativos al usar el Tm:YAG con la fibra de 273μm (10W a 50W) (p≤0,02) y de 550μm (10W) (p=0,04). Con el Ho:YAG se registró un incremento significativo al usar fibras de 273μm (a 10W y 20W) (p≤0,03) y de 365μm (10W) (p=0,04). Respecto al tamaño de las fibras, hubo una diferencia significativa al usar el Tm:YAG (a 20W y 40W) (p<0,05). La cámara termográfica registró un incremento medio de 8°C en la unión pieloureteral mientras que el resto del riñón no sufrió cambios significativos. Conclusione Los cambios de temperatura fueron mayores al usar el láser Ho:YAG respecto al Tm:YAG a configuraciones de poder similares para la ablación tisular. El mayor incremento de temperatura fue registrado en la unión pieloureteral desde donde el calor se disipaba al resto del riñón (AU)


Aim To measure the temperature dynamics at the renal surface and within the urinary tract when using Ho:YAG and Tm:YAG lasers for tissue ablation. Materials and methods Porcine kidneys were used. Both types of lasers with different configurations and fiber sizes were used through a flexible ureteroscope. The temperature at the renal surface was recorded using a thermal camera while the intrarenal temperature was measured using two thermal probes, the first one at the ureteropelvic junction and the second one at the calyx used for lasering. Temperature was determined at 0.5-1-3-5 and 10minutes. Results Recordings at the ureteropelvic junction and calyx revealed significant increases when using Tm:YAG with the 273μm (10W to 50W) (p≤0.02) and 550μm (10W) fiber (p=0.04). With Ho:YAG there was a significant increase when using 273μm (at 10W and 20W) (p≤0.03) and 365μm (10W) fibers (p=0.04). Regarding fiber size there was a significant difference when using Tm:YAG (at 20W and 40W) (p<0.05). The thermal camera recorded a mean increase of 8°C in the UPJ while the remaining areas of the kidney did not undergo significant changes. Conclusions Temperature changes were greater when using the Ho:YAG laser with respect to Tm:YAG at similar power settings for tissue ablation. The greatest temperature increase was recorded at the UPJ from where the heat dissipated throughout the kidney (AU)


Subject(s)
Animals , Models, Animal , Body Temperature , Kidney/surgery , Laser Therapy , Swine
4.
Actas Urol Esp (Engl Ed) ; 47(4): 221-228, 2023 05.
Article in English, Spanish | MEDLINE | ID: mdl-36379260

ABSTRACT

BACKGROUND: Radical nephroureterectomy (RNU) represents the gold standard treatment for upper tract urothelial carcinoma (UTUC); however, attempts have been made to treat upper urinary tract CIS (UT-CIS) conservatively. The aim of this study was to compare the outcome of patients with primary UT-CIS treated in our center by means of RNU vs. bacillus Calmette-Guérin (BCG) instillations. METHODS: This retrospective study included patients with diagnosis of primary UT-CIS between 1990 and 2018. All patients had histological confirmation of UT-CIS in the absence of other concomitant UTUC. Histological confirmation was obtained by ureteroscopy with multiple biopsies. Patients were treated with BCG instillations, RNU or distal ureterectomy. Clinicopathological features and outcomes were compared between RNU and BCG groups. RESULTS: A total of 28 patients and 29 renal units (RUs) were included. Sixteen (57.1%) patients (17 RUs) received BCG. BCG was administered via nephrostomy tube in 4 patients, with a single-J ureteral stent in 5, and using a Double-J stent in 7. Complete response and persistence or recurrence were detected in ten (58.8%) and seven (41.2%) RUs treated with BCG, respectively. Eight (27.6%) RUs underwent RNU, and 4 (13.8%) Rus distal ureterectomy. No differences were found in recurrence-free survival (p=0.841) and cancer-specific survival (p=0.77) between the RNU and BCG groups. CONCLUSIONS: Although RNU remains the gold standard treatment for UT-CIS, our results confirm that BCG instillations are also effective. Histological confirmation of UT-CIS is mandatory before any treatment.


Subject(s)
Carcinoma in Situ , Carcinoma, Transitional Cell , Urinary Bladder Neoplasms , Urologic Neoplasms , Humans , Nephroureterectomy/methods , Ureteroscopy/methods , Carcinoma, Transitional Cell/drug therapy , Carcinoma, Transitional Cell/surgery , BCG Vaccine/therapeutic use , Urinary Bladder Neoplasms/pathology , Retrospective Studies , Urologic Neoplasms/surgery , Carcinoma in Situ/pathology , Biopsy
5.
Leukemia ; 24(8): 1445-9, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20520635

ABSTRACT

Chronic myeloid leukemia (CML) is caused by the BCR-ABL hybrid gene. The molecular mechanisms leading from chronic phase (CP) to blast crisis (BC) are not understood. However, both the presence and the levels of BCR-ABL seem to be important for CML progression. BCR-ABL is under the transcriptional control of BCR promoter. Here we focused on the gene expression control of BCR and BCR-ABL upon myeloid differentiation in healthy donors (HDs), CP and BC patients. As previously reported, BCR-ABL is downregulated during myeloid maturation in CP patients. A similar pattern was detected for BCR (but not for ABL) in CP-CML and in HD, thus suggesting that the two genes may be under a similar transcriptional control. In BC this mechanism is similarly impaired for both BCR-ABL and BCR. These data indicate the presence of an 'in trans' deregulated transcription of both BCR and BCR-ABL promoters, associated with CML progression.


Subject(s)
Blast Crisis , Cell Differentiation , Fusion Proteins, bcr-abl/metabolism , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Proto-Oncogene Proteins c-bcr/metabolism , Base Sequence , DNA Primers , Fusion Proteins, bcr-abl/genetics , Humans , K562 Cells , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism , Polymerase Chain Reaction , Proto-Oncogene Proteins c-bcr/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...